Graft Polymer (UK) PLC Result of AGM (1225U)
July 28 2022 - 7:30AM
UK Regulatory
TIDMGPL
RNS Number : 1225U
Graft Polymer (UK) PLC
28 July 2022
28 July 2022
Graft Polymer (UK) Plc
("Graft Polymer", the "Company", and together with its
subsidiaries, the "Group")
Results of AGM
Graft Polymer (UK) Plc (LSE: GPL), a business focused on the
development and commercial production of polymer modification,
biological supplements, and nano-drug delivery systems, announces
that at the Company's Annual General Meeting ("AGM") held earlier
today, all resolutions were duly passed.
**ENDS**
For more information, please visit https://www.graftpolymer.com
or contact:
Graft Polymer (UK) Plc via Tavistock
Roby Zomer, Chairman
Yifat Steuer, CFO
Turner Pope Investments (Broker) +44 20 3657 0050
James Pope
Andy Thacker
Tavistock (Public Relations) +44 207 920 3150
Heather Armstrong graftpolymer@tavistock.co.uk
Katie Hopkins
About Graft Polymer
Graft Polymer is a UK incorporated holding company with an
innovative research and manufacturing facility, based in Slovenia.
The core business of the Group comprises polymer modification and
drug delivery systems developments. Established in 2017, the Group
has already introduced more than 50 products to the market.
The Group has developed a proprietary set of polymer
modification technologies, which can improve existing products and
processing methodologies by enhancing performance, simplifying
manufacturing, reducing material consumption, widening the choice
of feedstocks, and reducing costs.
In particular, the Group's techniques allow the combination of
otherwise incompatible polymers, facilitating the creation of
polymer composites engineered at a molecular level, that combine
the attractive properties of different input materials. This
enables customers to receive a synergism of properties in polymer
composites.
The solutions and products offered by the Group are designed to
improve performance, reduce raw materials consumption, and enhance
the physical characteristic values of finished products or improve
or modify their chemical interaction. In the past several years,
there has been increased emphasis by the industry as a whole on
applications of grafted polymers, which are produced by monomers
being covalently bonded and polymerised as side chains onto the
main polymer chain (the backbone).
In 2020, the Group launched a new division named GraftBio to
develop IP for Bio/Pharma applications. This includes a drug
delivery system to support and provide solutions to the market,
which had been heavily impacted by the COVID-19 pandemic. The
GraftBio division has been granted HACCP certification for its
production facility. The Group has developed a set of drug delivery
platforms that enable it to licence its DDS platform (IP) to MGC
Pharmaceuticals Limited ("MGC"; LSE: MXC) in relation to MGC's
CimetrA(TM) and CannEpil-IL(TM) products. The Group expects to
receive royalty payments resulting from the sale by MGC of
CimetrA(TM) and CannEpil-IL(TM) products.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
RAGUWAARUBUBUAR
(END) Dow Jones Newswires
July 28, 2022 07:30 ET (11:30 GMT)
Graft Polymer (uk) (LSE:GPL)
Historical Stock Chart
From Apr 2024 to May 2024
Graft Polymer (uk) (LSE:GPL)
Historical Stock Chart
From May 2023 to May 2024